FLAGYL I.V. INJECTION Rx
Generic Name and Formulations:
Indications for FLAGYL I.V. INJECTION:
Susceptible anaerobic infections. Surgical prophylaxis.
Infuse over 1 hour. Anaerobic infections: 15mg/kg (loading dose), then 7.5mg/kg every 6 hours; max 4g/day. Prophylaxis: see literature.
Pregnancy (1st trimester for trichomoniasis).
CNS disease. Discontinue if neurological symptoms occur. Severe hepatic disease: reduce dose. Candidiasis. History of blood dyscrasias. Monitor leukocytes before and after therapy. Elderly: monitor serum levels. Pregnancy (Cat.B). Nursing mothers: not recommended.
Avoid alcohol during and for 3 days after use. Do not give within 2 weeks of disulfiram (possible psychotic reactions). May potentiate oral anticoagulants, phenytoin, lithium. Antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. Potentiated by cimetidine, other hepatic enzyme inhibitors. Interferes with serum chemistry tests.
Seizures, peripheral neuropathy, GI upset, anorexia, constipation, headache, metallic taste, ECT changes, dysuria.
Tabs—50, 100; Caps 375mg—50; IV—24
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma